

#### DISCLAIMER

The following provisions apply to this presentation. Please consider its contents carefully.

#### **Currency of information**

The information contained in this presentation is current as at the date of this presentation or such earlier date as specified in this presentation.

#### **Summary information**

The information in this presentation is of a general nature only. It does not purport to be complete.

#### Not investment advice

The information contained in this presentation is not investment or financial product advice or any recommendation to acquire securities in McPherson's Limited (ASX: MCP). This presentation has been prepared without taking into account your investment objectives, financial situation or particular needs.

#### Company information

MCP's historical information in this presentation is, or is based on, information that has been released to ASX. This presentation should be read in conjunction with MCP's other periodic and continuous disclosure information lodged with ASX, which are available at <a href="https://www2.asx.com.au">www2.asx.com.au</a>.

#### Third party information

Certain market and industry data used in connection with this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither MCP nor any of its related bodies corporate, directors, employees, agents or advisers have independently verified such market or industry data.

#### Historical information

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as, and is not, an indication of future performance.

#### Forward looking information

This presentation contains certain forward-looking statements that involve risks and uncertainties. MCP can give no assurance that these expectations will prove to be correct. You are cautioned not to place undue reliance on any forward-looking statements. Actual results may differ materially from those anticipated in these forward-looking statements due to many important factors, risks and uncertainties including, without limitation, risks associated with future capital needs, general economic uncertainty and other risks detailed from time to time in MCP's announcements to ASX. MCP does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws.

#### Disclaimer

No representation or warranty, whether express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. You should carry out your own investigations and analysis of MCP and verify the accuracy, reliability and completeness of the information contained in this presentation.

Neither MCP nor any of its related bodies corporate, directors, employees, agents and advisers accept any responsibility for any loss arising from anyone acting or refraining from acting in reliance on the contents of this presentation.

# **AGENDA**

1. MCPHERSON'S TODAY

Grant

2. STRATEGY & OPERATIONAL REVIEW UPDATE

Grant

Donna & Lori

3. STRATEGIC GROWTH PLATFORMS

i. Core 6 brands, Key Channels

ii. Health Dawn

iii. International Expansion David, Jade & TCG

4. OUR UNIQUE CAPABILITIES

. Customer & Shopper education

ii. R&D / Innovation

iii. Sustainability

iv. Supply Chain

Lori

Donna

Donna

Paul

5. FINANCIAL UPDATE

Paul

6. SUMMARY & Q&A

Grant





## MCPHERSON'S - AT A GLANCE

FY21 Forecast Revenue \$200 - 205M

340+ Staff40% Customer facing

1,625 SKU's<sup>2</sup>5 No.1 Brands13 Categories<sup>3</sup>



1.2M
Points of Distribution
Globally



L4 Countries



11,000+

Customer Stores +50%1

of Australian
households
purchased an MCP
brand in the last 12
months

<sup>1</sup> IRI Shopper Panel Data MAT 31/1/21 (Multix 50.2%; Manicare 10.2%; Lady Jayne 3.8%; Dr LeWinns 1% HH penetration)

<sup>2.</sup> MCP Saleable SKU's, A,B, C & N Saleable on the 19th May '21

<sup>3.</sup> Categories. Australian IRI Categories MCP competes in.

# HEALTH, WELLNESS & BEAUTY - A STRONG FUTURE

#### WE'RE OPERATING IN A \$15.2 BILLION MARKET

HEALTH & WELLNESS<sup>1</sup> (\$7.5 Billion, +5.7% vs Year Ago)

BEAUTY<sup>1</sup> (\$7.7 Billion, +4.6% vs Year Ago)



#### NATURAL HEALTH

Immunity & Protection

Sleep & Mood

Joint & Movement

Digestive Health











# HEALTHY SKIN & BEAUTY

Cosmeceutical
Australian Natural
Essential Beauty
Clean Beauty















# HEALTH, WELLNESS & BEAUTY - A STRONG FUTURE

#### **HEALTH & WELLNESS**

BROAD PENETRATION<sup>1</sup>

78%

AUSTRALIAN'S PURCHASE COMPLEMENTARY MEDICINE

Past 12 months

AGEING POPULATION<sup>2</sup>

15% to 22%

Over 65 YRS 2017 Vs 2057

SIZE, STRENGTH, & GROWTH<sup>3</sup> \$7.5B

AUSTRALIAN HEALTH & WELLNESS CATEGORY

COVID IMPACT<sub>7</sub>

64%

GLOBAL CONSUMERS ARE FEARFUL FOR THEIR HEALTH

#### BEAUTY

MARKET POSITION<sup>4</sup>

MCP No. 2

AUSTRALIAN BEAUTY
SUPPLIER TO PHARMACY

CONSISTENT CATEGORY GROWTH<sup>5</sup> +4.8%

GLOBAL BEAUTY INDUSTRY EST. 4YR CAGR to 2025

STRONG ANTI AGEING BEAUTY NEEDS<sup>6</sup> 82% 93%

93% 97%

CHINA USA

UK

TOP 2 BOX SURVEY RESULTS


1.Complementary Medicines Australia: Industry Audit & Trends 2020
2. Source: Older Australia at a glance; Australian Institute of Health & Welfare
3.IRI MarketEdge Pharmacy & Grocery
4.IRI market data: MAT FEB 21

5. Statista Beauty & Personal Care Worldwide Outlook 2021 to 2025 7

## MCP - WINNING IN LARGE HW&B CATEGORIES

CATEGORY	Size	MCP Share
Vitamins Mineral Supplements	\$2B	<1%
Skincare	\$1.3B	2%
Haircare	\$794	<1%
Bags Wraps Foils	\$447M	28%
Beauty Accessories	\$189M	40%
Footcare	\$93M	6%
Hair Accessories	\$56M	35%
Cotton	\$48M	61%

#### MCP CATEGORIES: \$SIZE & GROWTH & AVG RETAIL PRICE





# STRATEGIC INTENT

Health, Wellness and Beauty remains our core focus

Our near-term focus will be on the growth potential in existing categories from our established brands, capabilities, customers and channels Growth potential through greater collaboration, alignment and simplification of purpose, including a simplification of the JV strategy

Brand acquisitions consistent with this definition have been a key component of our transition and will continue to be assessed – but with clear guard rails

### OPERATIONAL REVIEW OUTCOMES

#### TARGET \$300M SALES & \$50M EBIT IN FY26



- Laser focus on realizing and leverage domestic market capabilities: strong brand positions, executional resources and relationships
- Drive growth by tapping into adjacent markets and R&D



- The unique" ancient wisdom and modern medicine" hybrid positioning resonating well with consumers
- Ranging upside in Australian Pharmacy and reset from zero in New Zealand
- NPD is a significant growth opportunity



- De-risking reliance on one brand, one channel, one geography in Export
- Leverage and build on key partnerships in Export, whilst keeping realism in expectations.



Amend overheads to reflect the "reset" level of profitability in F21

- Drive efficiencies in Supply Chain and Distribution
- Deliver procurement and component price opportunities
- Reduction in overheads while preserving the core capabilities that drive our proposition

#### A. Major Focus Items of the Operational Review drive changes in approach and expectations in 4 key areas:



Greater opportunity in the domestic market than previously appreciated:

- Brand positions, executional resources and relationships are strongest.
- Opportunity to better leverage these capabilities to support sales opportunity via better ranging, customer and channel expansion
- And brand growth is expected to be greater via adjacency opportunity and greater focus on innovation.













# THESE INITIATIVES ARE TARGETED TO DELIVER \$230M SALES & \$29M EBIT BY FY26

#### A. Major Focus Items of the Operational Review drive changes in approach and expectations in 4 key areas



The acquisition process and the recent review of Global Therapeutics has driven a sound understanding of the opportunities in this space

- The unique "ancient wisdom and modern medicine" hybrid positioning resonates well with consumers
- Ranging upside is significant in Australian Pharmacy and will be reset in New Zealand
- A significant growth opportunity exists through acceleration of new product development (NPD)





THESE INITIATIVES ARE TARGETED TO DELIVER \$30M SALES & \$7M EBIT BY FY26

#### A. Major Focus Items of the Operational Review drive changes in approach and expectations in 4 key areas




Build on the established success of Dr LeWinn's in China - de-risking reliance on one brand, one channel, one geography in international

- Continue to leverage and build on key partnerships, whilst keeping realism in expectations
- Renewed ranging and support for Dr LeWinn's will increase the breadth of distribution points beyond current levels
- Selectively use Cross Border E-Commerce (CBEC) into other large markets of relevance
- We are progressing non China markets and will leverage for other portfolio brands of relevance



THESE INITIATIVES ARE TARGETED TO DELIVER \$40M SALES & \$8M EBIT BY FY26

#### A. Major Focus Items of the Operational Review drive changes in approach and expectations in 4 key areas



We will amend overheads to reflect the "reset" level of profitability in FY21

- Efficiencies will be gained in Supply Chain and Distribution, as we consolidate businesses acquired and optimise
- We will deliver procurement and component price opportunities for formulated brands of scale that are material
- Overheads will be addressed while preserving the core capabilities that drive our proposition

# THESE INITIATIVES ARE TARGETED TO DELIVER \$6M EBIT BY FY23

### STRATEGIC & OPERATIONAL REVIEW TARGETS

#### COST EFFICIENCY AND COST BASE AMENDMENTS PROGRAM

Full Year EBIT impact rises from ~\$3M in FY22 to ~\$6M in FY23

- Warehouse Efficiencies programmed efficiencies evolving to ~\$0.8M in FY23 with immediate capture of \$0.4M in FY22
- 2. Delivery Optimisation evolving from \$0.6M in FY22 to \$1.0M in FY23
- 3. Procurement and product cost formulation (COGS reduction) \$1.0M in FY23
- 4. Selling, General and Administrative (SG&A) cost improvements of \$2.2M in FY22 evolving to \$3.2M in FY23

(\$M)	FY22	FY23	Annualised Cost Efficiencies
Warehouse	\$0.4	\$0.4	\$0.8
Delivery	\$0.6	\$0.4	\$1.0
COGS Reduction	\$0.0	\$1.0	\$1.0
SG&A	\$2.2	\$1.0	\$3.2
Total	\$3.2	\$2.8	\$6.0

# STRATEGIC & OPERATIONAL REVIEW TARGETS

Confidence in growth

We anticipate FY26 sales of \$300M and EBIT of \$50M

# Clear building blocks

Sequenced deliverables to illustrate the pathway to this performance outcome

# Enhanced capability

Preservation of core value drivers, but in concert with cost optimisation delivery

# Better performance expectation

Leading to a better performance expectation in a lower risk environment



#### STRATEGIC PRIORITY 1




# 6 CORE OWNED BRANDS & KEY CHANNELS

# MARKET LEADING BRANDS WITH HEALTHY BRAND METRICS

# STRATEGIC PRIORITY 1



#1 Australian Cosmeceutical
Brand
TOP 10 FACIAL SKINCARE
PHARMACY



#1 Hair Tools & Accessories +1.9 SHARE POINTS PHARMACY & GROCERY



#2 Natural Haircare in Pharmacy +1.6 SHARE POINTS PHARMACY & WOOLWORTHS



#1 Sustainable Wraps & Foil #1 Foil, Bake, Garbage & Freezer Bags



#1 Beauty Tools
& Accessories
+2.2 SHARE POINTS
PHARMACY & GROCERY



#1 Cotton +2.6 SHARE POINTS PHARMACY & GROCERY

# CORE BRANDS: 5 YEAR VISION

# 5

#### STRATEGIC PRIORITY 1



Drive market share gains in pharmacy through inner and outer beauty innovation TOP 3 FACIAL SKINCARE



Connect with consumers through style innovation and grocery channel expansion 39% SHARE (+4.0%)



Build scale through channel expansion and efficacious natural credentials +102% GROWTH



Lead and partner with retail customers to drive sustainable transformation 36% SHARE (+7.3%)



Lead category growth through real estate & salon at home innovation 32% SHARE (+2.7%)



Drive cotton leadership and expand equity into adjacent categories
+\$6.2M RETAIL SALES GROWTH

## INNOVATIVE SKINCARE RESONATING WITH CONSUMERS



#### DR. LEWINN'S

- Strong track record for successful new product launches to drive share gains
  - New Marine Collagen Liquid Shots ranked within Top 5 Facial Skincare NPD in the latest Quarter
  - Within Chemist Warehouse Marine Collagen Liquid Shots ranking #5
     in Dr. LeWinn's range since launch in February
  - New potent Eye Serum launched in China leading up to 6.6 Festival and major Domestic activation planned in November 2021
  - Renovation of core ranges with increased clinicals 2022
  - 34 Dr. LeWinn's R&D projects in the pipeline









# HIGH PERFORMANCE NATURAL SKINCARE AND HAIRCARE



STRATEGIC PRIORITY 1

#### A'KIN

- Boosting clinical claims to build scale in pharmacy and grocery
  - 31 clinically proven products within A'kin range
    - Clinically proven A'kin Hair Mask contributing 10% to A'kin Haircare range
    - Clinically proven A'kin Deodorant increasing year on year +139%
  - Build scale and awareness to drive consumer penetration
    - Grocery expansion across haircare, skincare and personal care
    - Invest in new brand campaign "Approved by Nature, Clinically Proven"
    - Evolve packaging and new products in line with clean beauty macro trend







# LEVERAGING MACRO TRENDS TO DRIVE CATEGORY GROWTH



#### **MANICARE**

- \$68M¹ masterbrand connecting through beauty at home macro trend
  - Continued investment in merchandising real estate and on-line to engage consumers across all path to purchase touch points
  - Focus on skincare beauty tools segment growing +37% to drive increased brand penetration and higher value purchases
  - New lash technologies year on year driving increased consumer demand
  - Partnering with retailers to bring affordable technology innovations to the mass market










# CONSUMER LED INNOVATION DRIVING DOUBLE DIGIT GROWTH



#### **LADY JAYNE**

- Increasing leadership through accessible styling across channels
  - Covid accelerating category growth (+16%) with Lady Jayne leading the charge (+23%) through innovation and high social reach (6.7M)
  - Expansion in grocery represents \$3M incremental retail sales opportunity
  - Leverage leadership in hair brush innovations as the entry point into grocery
  - Target high value hair accessories with fast fashion NPD via expert panel and runway trends









# STRENGTHENING OUR COMMITMENT TO SUSTAINABILITY



#### **MULTIX**

- Transforming the category with sustainable products
  - Continue to drive Multix as the consumer brand of choice to expand distribution:
    - 50.2% household penetration for Multix brand
    - 79% of sustainable buyers buy Multix Greener
  - Upsize packs to support sustainability ranges as the everyday norm
  - Lead sustainable innovations to protect future generations





















# INCREASING SUSTAINABLE FOOTPRINT THROUGH PARTNERSHIPS



#### **SWISSPERS**

- Trust, quality and care for the planet
  - Covid shift towards trusted brands saw Swisspers achieve 61% share high in the cotton category
  - Swisspers expanded sustainable range with 5 cotton tip paper stem products and 6 Eco Biodegradable Wipes launched in the last 12 months
  - Continued drive for sustainable, locally sourced cotton enhancements
  - Partnering with retailers with plastic reduction initiatives:
    - 562M plastic cotton tips eliminated in supermarkets since change over to paper stems









# TARGETED ADJACENCIES TO WIN AND EXPAND OUR EQUITY





- Manicare expansion into Power Beauty Tools targeting mass channels at affordable price points
- Leverage salon at home beauty trend with clinically proven facial and body tools
- High retail price points \$50 to \$130 drives category value
- Quality, trust and efficacy to target +2.7 share point gains



- Swisspers equity expansion into high growth Baby category
- Baby Needs segment growing +20%
- Target \$3.5M Swisspers Baby Cotton milk range
- 65% of parents are willing to pay more for products that contain Natural plant ingredients.






- Transformation of Stratton from a small, bottom shelf product to a proud Men's Grooming brand. Target \$2.2M retail sales
- Targeting everyday grooming and high demand Beard care




#### Sugar, Baby




- Sugarbaby refresh targets \$42M<sup>1</sup> pharmacy tanning category
- Gen Z<sup>2</sup> focused brand 5 million Australians, on average spent \$448 on cosmetics and skincare in 2020
- Consumers opting for in-home beauty and skin treatment following COVID19
- Beauty e-commerce<sup>3</sup> grew 76% v
   YA driven by 'skinfluencers'

# POSITIONED FOR GROWTH





#### TOTAL DISTRIBUTION POINTS IN ANZ BEAUTY



MCP Field and Customer Service Team call on >7,000 Australian & New Zealand Pharmacy and Independent Grocery outlets

# RESPONDING TO SHOPPER BEHAVIOUR SHIFTS FY21

Pivot to online



INCREMENTAL RANGING

+ 1,355

INCREMENTAL ONLINE DISTRIBUTION POINTS

INVESTMENT

+ 30%

INVESTMENT IN MAJOR
CUSTOMER ONLINE PLATFORMS v
FY20

In store engagement

53%<sup>1</sup>
SHOPPERS CHANGE MIND IN

STORE

OFF LOCATIONS

+ 39%

**INVESTMENT** 

EDUCATION & RECOMMENDATION

30

EDUCATION BASED ACTIVATIONS
IN PHARMACY

# INVESTMENT IN SHOPPER FY22



Engaging shoppers in their path to purchase



#### **INVESTMENT**

+22% investment online & social vehicles

\$

#### POINT OF PURCHASE

+23% spend in off locations v FY21 Continued investment in category solutions




#### **EDUCATION & RECOMMENDATION**

38 education based activations in Pharmacy

# STRATEGIC PARTNERSHIPS






32


# ANZ 5 YEAR GROWTH DRIVERS





# TOTAL ANZ: KEY DELIVERABLES & TARGETS

#### SALES: BASE AUSTRALIA & NZ BUSINESS\*



 $\bullet$  Base ANZ Business includes Singapore & excludes the Health Division SALES FY21 - FY26 Target

#### STRATEGIC PRIORITY 2



# HEALTH AND WELLNESS A NEW GROWTH PLATFORM

### HEALTH & WELLNESS: A NEW GROWTH PLATFORM



#### STRATEGIC RATIONALE

Enter in to the health and wellness category and provide a new platform for growth



#### **DELIVERABLES**

- Acquired Global Therapeutics to form McPherson's Health Division
- 71% of the Health team have a Health qualification
- Regulatory and innovation capability
- Fusion Health brand strong resonance with consumers

Product and market expansion



- Global category valued at over US\$50B<sup>1</sup>
- Australian vitamin & dietary supplement category AUD\$3.9B<sup>2</sup>
- Growth plan for the international and domestic markets
- New product development focused on fast growth segments

Ability to leverage across platforms and generate operating efficiencies



- Strong supply chain focus
- Health qualified team now driving Happy Flora and Soulful
- Operational efficiencies in distribution
- Leverage capability in international markets

2. Complementary Medicines Australia: Industry Audit and Trends 2020

<sup>1.</sup> Statista: Size of the vitamin supplement market worldwide 2019

## MCP HEALTH BRANDS A KEY GROWTH PILLAR



#### Momentum building...

- Inventory and in-stock position strongest since February 2019
- April '21 strongest sales month since September '19 (Excluding March '20 COVID-19 impact)
- Focused retailer and consumer campaigns
- Operational review kick started 5 year strategic growth plan
- Health capability transitioned into McPherson's



## TRANSITION TO MCPHERSON'S HEALTH



## Successfully transitioned into McPherson's warehousing and IT systems in March

- April 2021 go live, McPherson's Health full transition
- Products currently manufactured by Blackmores moving to an Australian contract manufacturer as per acquisition requirement
- Q4 FY21 Health Division commenced selling A'kin and JV brand Happy Flora into the health food channel
- Warehouse efficiencies & delivery optimisation captured in supply chain cost based amendments program



## HERBAL & TRADITIONAL PRODUCTS A HIGH GROWTH SUB SEGMENT



78%<sup>1</sup> of Australians have purchased at least one form of complementary medicine in the last year

83%<sup>1</sup> of
Australian women
have purchased at
least one form of
complementary
medicine in the last
year

1 of 3<sup>1</sup> Australians using complementary medicines to manage symptoms of chronic pain

**52%**<sup>2</sup> herbal, traditional or complementary supplements consumed daily

## \$3.9B VITAMINS / NATURAL HEALTH CATEGORY<sup>1</sup>



Australian complementary medicines

55%<sup>1</sup>
2014/2019
CAGR

Herbal & Traditional Products

57%<sup>1</sup>
2014/2019
CAGR

<sup>1.</sup> Complementary Medicines Australia: Industry Audit and Trends 2020

## CONSUMER INSIGHTS VALIDATE FUSION'S UNIQUE & STRONG BRAND POSITIONING



On initial exposure the Fusion Health brand appears modern and credible with clear cues to nature, eastern philosophies and current scientific approaches

#### Red palette

Strong cues to Chinese medicine principles or ingredients

#### Ancient wisdom

Suggests roots in Chinese medicine. Respected and believable



#### Yin and Yang

Suggests balance between old and new or East and West

#### Planticonography

Natural, herbal, plant-based products

#### Modern medicine

Safe, reassuring, underpinned by science, rigorous testing

#### **Fusion**

Modern terminology, scientific, on trend (heard a lot in cooking) feels both exciting and safe

## FOUR CORE PILLARS - TARGETING \$30M IN SALES BY 2026



1

Pharmacy Growth /
Improve Core Range
Compliance

- Double pharmacy distribution
- · Improve 'shopability'
- Merchandising solution
- Create destination

2

New Zealand & eCommerce

- Refresh and relaunch NZ
- New Market Singapore eCommerce
- Grow eCommerce through customer partnerships

3

New Product Development

- Ideation plan developed
- Collaboration with ingredient experts exploring new opportunities

4

Health Food & Brand Opportunities

- Grow Health Food share
- Targeted investment driving core brands
- Education solutions enabling quality consumer experience
- Represent all MCP health focused products in market

## HEALTH & WELLNESS DIVISION TARGETING \$30M BY FY26





#### STRATEGIC PRIORITY 3




# EXPAND INTERNATIONAL FOOTPRINT

## EXPAND OUR INTERNATIONAL FOOTPRINT




#### i. REBALANCING INTERNATIONAL GROWTH



#### ii. MCP SKIN CARE & HEALTH PORTFOLIO (\$M)

INCREMENTAL SALES: FY21 TO FY26 TARGET





## USA - WIN WITH DR. LEWINN'S VIA ONLINE



### By FY26 target USA as 3<sup>RD</sup> largest Dr LeWinn's market outside Australia & China

SIZE

USD\$30B1

Skin care market ('21) Growing at 3.7%

#### **PURCHASE INTENT**

DRL STRENGTH

STRATEGY

**MARKET** 

**INSIGHT** 

71%4

Top 2 Box Purchase Intent - Dr LeWinn's Triple
Action Day Defense Anti-Ageing Serum

#### **ONLINE TO OFFLINE**

amazon

In FY22 target the \$1.3bill in retail sales of skincare, driving share gains

**STRENGTH** 

**42**%<sup>2</sup>

Shop online for beauty (Top 3 channel), with online share forecast to reach 48% by '23.

#### **BRAND APPEAL**

15%4

Top Box "Very Appealing score"

DRL USA consumer research

#### **BEAUTY E-COMMERCE PLATFORMS**

## TARGET 3

Top 10 Beauty E-Commerce platforms to expand penetration by FY23

#### **MARKET SITUATION**

86%<sup>3</sup>

Beauty sales online not from the Top 20 manufacturers

#### **CONSUMER NEEDS**

## Anti-Ageing<sup>5</sup>

57% claim as Top functional need Females 30 to 50

#### SPECIALTY RETAIL DOORS

## TARGET 250

By FY24 specialty retail doors over the next 2-3 years from Sephora, ULTA Beauty or Bath & Body Works

<sup>1.</sup> Statista 2021 USA Skincare Retail Sales Value

<sup>2&</sup>amp;3. NPD Online sales of prestige beauty -19th Nov '20

## UK & EU- PACED ROLLOUT FOR DR. LEWINN'S



#### MARKET INSIGHT

CHANNEL

**OPPORTUNITY** 

CONSUMER

INSIGHT

US\$3.9B

UK

Skin care market ('21)
Statista

#### GERMANY

US\$4.6B

Skin care market ('21)
Statista

#### FRANCE

US\$4.0B

Skin care market ('21)
Statista

#### UK E-COMMERCE

### 41%

prestige skincare sales in (Jan-Oct), growing at +54% Vs YA.

\* NPD Online sales of prestige beauty -19th Nov '20

#### **UK PARTNER**

#### Online partner

Specialist online platform partner identified. Commercial terms commenced

#### RUSSIA

69%

Russian female consumers plan to continue buying cosmetics online

\* Miguel Agency Russia Survey 2020

#### **PURCHASE INTENT**

#### 43%

Top 2 Box Purchase Intent - Dr LeWinn's Triple Action Day Defence Anti-Ageing Serum\*

#### POSITIVE APPEAL

33%

Consumers find Dr LeWinn's very appealing when viewed video for the first time\*

#### **TREND**

UK, FR, GER Sign of recovery

+33%

UK total prestige beauty increase 1st half 2020 \* NPD Group 2021

Online survey of 3103 20 - 50yr old women across UK from 24th to 27th April 2021

#### Strategy



 Top 5 online beauty platform, delivering 500 brands and 30,000 products

#### FEELUNIQUE



- Target a further 2 out of the Top 10 Beauty E-Commerce platforms to expand penetration.
- Launch in Top 200 specialty retail doors from Boots (2,336 UK doors) or Waitrose & Partners (335 doors)

#### lookfantastic



WAITROSE & PARTNERS





- Paced European market expansion 1 market/year
- Penetrating key local retailers and e-comm platforms



By FY26 Dr LeWinns for UK & Europe is targeted to be the 4th largest region (sales revenue) for Dr LeWinn's after Australia, China & the USA

## EXPAND ASIA & MENA\* SKINCARE BRANDS WITH EXISTING **PARTNERS**



**MARKET** 

**INSIGHT** 

CHANNEL

**OPPORTUNITY** 

\$235B<sup>1</sup>

SIZE

ASIA/MENA MARKET SIZE 2021

Beauty & Personal Care

**GROWTH** 

+8.5%2

MENA Beauty & Personal care set to grow twice as fast as global ('21 to '26) **GDP** 

ASEAN-63

Increasing share of global GDP and forecast to increase post COVID

ASIA

+55%4

Of consumers claim they will permanently change their online shopping behavior

**MENA** 

19.5%

to 30.2%<sup>5</sup>

User penetration 2021-2025

**E-COMMERCE** 

60%<sup>6</sup>

of Dr LeWinn's & A'Kin FY21 forecast sales are expected to come from E-Commerce

#### **DEMAND FOR NATURAL**

CONSUMER INSIGHT

>50%7

of consumers in Singapore look for products that are parabenfree, cruelty-free, natural, fragrance-free and sls-free

**ANTI AGEING** 

98%8

of consumers in Singapore look to prevent the signs of ageing on their skin

**TREND** 

80%9

of consumers would continue to shop online after covid lockdown (Singapore)

#### Strategy

#### **KEY GROWTH MARKETS**

#### Vietnam

Highest growth in skin care in Asia (ex – China & Australia)

#### Malavsia

- · 2nd highest growth in skin care in Asia
- · Neighbours Singapore provides economies of scale

#### Gulf Cooperation Council (GCC)

 Distributors aligned with growth opportunity for Dr LeWinn's across GCC

#### **KEY RETAILERS FY22**

Accelerate penetration in Top 5 beauty platforms







lookfantastic\*

Target top 300: Watsons stores (6,300 stores, 11 countries) or Guardian stores (715 stores) for Dr LeWinn's & Akin core ranging



watsons

5.Statista: Asia ecommerce personal care penetration Asia 2021

<sup>1.&</sup>amp;2. Statista 2021 Outlook - personal care / ecommerce Asia & United Arab Emirates

<sup>3.</sup> IMF, Macrobond, Bloomberg, ANZ Research

<sup>4.</sup> Euromonitor International COVID-19 Voice of the industry survey Arpil-2020

## DR. LEWINN'S - A STRONG BRAND IN CHINA



\$A80M<sup>1</sup>
underlying brand value
in the hands of the
Chinese consumer

Despite challenging market conditions YTD demand in China remains stable at -2%<sup>3</sup> in value

9% of Chinese female respondents found Dr. LeWinn's very appealing as a brand<sup>2</sup>

CBEC remains strategically important for Dr. LeWinn's growth in China

#### THE FUTURE

#### **Exclusive partnership**

- Measurable returns from a growing channel
- Direct engagement with resellers as brand advocates

#### Strengthening of Partnership

- Building the consumer base
- Expanding sales opportunities within the relationship model

#### **Elevating Marketing Activation**

- New marketing platforms and media
- Expanded marketing support for the brand

#### New Partnerships TCG GROUP

Engaging in new relationships with expertise to support our existing partners in driving expansion

<sup>1.</sup> Access Corporate Group Brand Team Sales Report FY21 YTD End March Dr. LeWinn's Volume & Value

<sup>2.</sup> ADNA Research 3504 women asked in an online questionnaire in Tier 1 and Tier 2 cities, May 2021

<sup>3.</sup> Access Corporate Group Internal Data as quoted in MCP ASX Announcement 29th April, 2021

## CHINA LANDSCAPE CONTINUOUSLY CHANGING



Strong Growth in China CBEC Sales<sup>1</sup>

Consistent growth between 2018 and 2021 in CBEC<sup>1</sup>

Total ecommerce in China is expected to grow 44% by 2024<sup>2</sup>



Leverage strength in consumer demand in China

Dr. LeWinn's is playing in the right channel.

Opportunity to expand scope within ecommerce

".....it's unlikely that all of the...sales...that disappeared as the Daigou trade to China slumped will eventually return." 3

> "Brand AU" continues to face challenges requiring agility in approach



Dr. LeWinn's was sheltered from a bigger impact as a result of the exclusive ABM relationship

Brands must adapt to the changing market conditions and how they access and keep the attention of consumers

COVID-19 accelerated an ongoing trend of consumers in China shifting towards

online channels.4

The pandemic triggered a self-care, beauty & skincare boom in China



Brands must connect with the demands of the Chinese consumers and be direct in their marketing messages to leverage trends and keep up with the pace of the market



RAND ARCHITECTS

China Beauty Market worth 600B RMB by 2023.<sup>5</sup>

Anti Ageing represents nearly 3/4 of the skincare category in China and is growing +63% year on year.6



With the consumer base and demand for skincare in the CBEC space growing, the key is knowing how to connect with Chinese consumers in a meaningful way.

https://www.tmogroup.asia/tmos-2021-china-ecommerce-insights/

China Skinny 2021 Skincare & Beauty Tracker

Australian Financial Review, 22 April 2021

https://www.mckinsey.com/~/media/mckinsey/featured%20insights/china/china%20still%20the%20worlds%20growth%20engine%20after%20covid%2019/mckinsey%20china%20consumer%20report%202021.pdf

Euromonitor China Cosmetics Industry Report 2020

China – Beaute Research Retail Panel – Skincare Growth Contributors

## FUSION HEALTH CBEC OPPORTUNITY



Health Supplement market size expected to rise 280B RMB by 2023<sup>1</sup>

CAGR forecasted at 14% between 2019 and 2023<sup>1</sup>



Accelerate Local Market
Activation

Fusion Health opportunity as the demand grows for Health Supplements in China

Australia & USA leaders in Health Supplements for the China market.<sup>2</sup>

"Brand AU" dominates with 22.3% market share in cross border and social ecommerce. <sup>2</sup>



Demand for Australian
Health Supplements has not declined.

This, despite the issues facing Australian brands in China.

Health Supplement purchase intent increased among Chinese consumers. <sup>2</sup>

Increased health awareness since the pandemic has resulted in increased purchase intent for Health Supplements.<sup>2</sup>



Leverage growing consideration for health & safety

Building the marketing foundations in China will help connect Chinese consumers with Fusion Health

### **TCG GROUP**

BRAND ARCHITECTS

Traditional Supplements are most favoured.<sup>1</sup>

Chinese online shoppers favour traditional and nutritional product types.<sup>1</sup>



**Driving High Conversion** 


Fusion Health offers a natural connection between use and ingredients for Chinese Consumers which can drive high conversions in online shopping

- 1. <a href="https://www.tmogroup.asia/health-supplement-report-2020-chinese-market/">https://www.tmogroup.asia/health-supplement-report-2020-chinese-market/</a>
- 2. Vitamin-and-Health-Supplements-market-in-China-report-by-daxue-consulting

## INTERNATIONAL EXPANSION TARGETING \$40M BY FY26



#### SALES: INTERNATIONAL EXPANSION





## EDUCATING OUR PEOPLE, CUSTOMER AND SHOPPER

#### **SHOPPER**

+58 how to videos

## MCPHERSON'S ACADEMY

+200 active participants per month

## QUALIFIED TRAINING TEAM

6 Qualified naturopaths
2 Qualified beauty advisors



3 M Views
How to tutorials



30 Education based activations



+2000 Retail assistants trained




14 Customer events



30 Internal training events



## INNOVATION SUCCESS DRIVING SUSTAINABLE GROWTH





#### Foreign market registrations

- 1. Australia
- . India
- 3. Thailand
- 4. Japan
- 5. UAE

- 6. South Korea
- 7. Malaysia
- 8. Singapore
- 9. Philippines
- 10. Indonesia



EXPANSION INTO BEAUTY NUTRITION



**#1 HAIR ACCESSORIES NPD** 



#1 NATURAL HAIRCARE SHAMPOO & CONDITIONER NPD



#1 COTTON SUSTAINABLE NPD

## SUSTAINABILITY - OUR GOALS

#### **OUR GOALS**

# MORE. LESS. NONE Sustainable Development. Reduced Environmental Footprint

#### SOURCE RESPONSIBLY

Reduce Operational Impact. Collaboration. Transparency

## PEOPLE & COMMUNITY

Sustainable Trusted Organisation. Improve Society

#### WHAT WE'LL DO

- Reduction in Total Greenhouse Gas Emissions with an aim to achieve net zero Scope 1 and 2 carbon emissions by 2030
- Reduce the amount of non-recyclable, non-reusable or non-compostable packaging in our products by at least 25% by 2025
- Implementation of the Australasian Recycling Label on at least 60% of our Core Owned and JV products by 2022
- Continue to drive a modern slavery management framework in line with Australian Modern Slavery Act
- Have full traceability or certification for critical ingredients and components by
   2025

### Become a certified B-Corp by 2025

Annually report on our performance against our stated commitments and goals

## AD DRESSING UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS











## GAIN EFFICIENCIES AND SAVINGS ACROSS SUPPLY CHAIN

**DAILY DELIVERIES AVAILABLE CAPACITY STAFF RETENTION** +40% 7,600+**ADAPTABLE** & FLEXIBLE Significant headroom in pick line 1.600 Australian Postcodes Tenure > 19 Years **SUPPLY CHAIN COSTS COVID RESPONSE ALTERNATE SUPPLY** Top 150 SKUs 88% \$7.5M hard savings **EFFICIENCY COVID** response Last five years China based supply can be sourced from alternate country TRUSTED PARTNERS **ADAPTING** MCP HEALTH 8 **OUT** Confirmed supply MCP 60% formulated product **FUTURE** 20 IN (incl Health) Health ex Blackmores now at Aware **PROOFING** Exit and entry of Brands into MCP facility



## SALES & EBIT TARGET SUMMARY - 5 YEAR PLAN

	SALES (\$M)		UNDERLYING EBIT (\$M)
All figures \$M	FY21 Forecast	FY26 Target	FY21 FY26 Forecast Target
Total Australian and NZ Business <sup>1</sup> Health & Wellness <sup>2</sup> International <sup>3</sup> Cost optimisation	\$182 \$10 \$8	\$230 \$30 \$40	\$29 \$7 \$8 \$6
Total	\$200	\$300	\$10 - \$13 \$50

<sup>1.</sup> Total ANZ Business includes Singapore (base business only) & excludes the Health Division

<sup>2.</sup> Health & Wellness = Fusion Health & Oriental Botanicals

<sup>3.</sup> Countries include China Dr Lewinn's, China other, USA, UK, Europe, Asia & Middle East/North Africa

## STRONG BALANCE SHEET PRESENTS OPPORTUNITY

#### Strategic M&A

Management will continue to review strategic, complementary, EPS accretive M&A opportunities

# Capital management initiatives

Capital Management initiatives put on hold throughout the bid process will be reconsidered

## High dividend payout ratio

Current dividend policy is to pay a minimum of 60% of underlying NPAT subject to cash requirements

## Return of high franking credits

Franking credits currently total ~\$25M



6. SUMMARY

## STRATEGIC & OPERATIONAL REVIEW TARGETS

#### Confidence in growth

We anticipate FY26 sales of \$300M and EBIT of \$50M

## Clear building blocks

Sequenced deliverables to illustrate the pathway to this performance outcome

## Enhanced Capability

Preservation of core value drivers, but in concert with cost optimisation delivery

## Better performance expectation

Leading to a better performance expectation in a lower risk environment

